Table of Contents
<< Previous Issue | Jan 2011 (Vol: 2011, Issue: 1) | Next Issue >> |
- Section: Joint Venture
-
Sanofi-aventis Forms Covalent Drug Discovery Partnership with Avila Therapeutics in Oncology
- Section: Licensing
-
Oncolys Out-Licenses Phase II HIV Drug to Bristol-Myers Squibb
-
Xoma Partners with Servier to Develop and Commercialise its Lead Anti-Inflammatory Drug
- Section: Mergers & Acquisitions
-
Reckitt Benckiser to Acquire India’s Paras Pharmaceuticals for US$725 M
-
Gilead Strengthens its Early-Stage Pipeline by Acquiring Arresto Biosciences
-
Biogen Idec Expands its Neurology Pipeline by Acquiring Three Programmes from Neurimmune
-
Biotie Therapies Expands CNS Pipeline with Acquisition of Synosia Therapeutics
- Section: Research & Development
-
GlaxoSmithKline Forms US$650 M Epigenetics Alliance with Epizyme
-
Pfizer Licenses Seattle Genetics’ Antibody-Drug Conjugate Technology
-
Merck Serono and Domain Therapeutics Partner to Develop Positive Allosteric Modulators for Parkinson’s Disease
-
Theraclone Sciences Signs its First Major Antibody Deal with Pfizer